- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00981851
Interaction in Chronic Obstructive Pulmonary Disease Experiment (ICE)
A Hazardous Combination of Cigarette Smoking and Bronchodilation in Chronic Obstructive Pulmonary Disease
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
COPD currently is one of the most frequent diseases. In more than 80% of COPD patients, the disease is caused by smoking. About half of the COPD patients are active smokers, although smoking is also the most important prognostic factor. Also, smoking is an important cause as well as an important prognostic factor in cardiovascular disease. The corner stone of medical treatment in COPD is bronchodilation; more than half of the patients use a long-acting bronchodilator. An increase of the pathogenic effect of smoking by an increased lung function after bronchodilation is likely though, since more pathogenic particles would penetrate the lung. We hypothesize that bronchodilators increase cardiovascular disease in COPD patients who smoke.
In order to demonstrate the basic mechanism of our hypothesis, COPD patients receive a bronchodilator at one time and a placebo at another time, preceded and followed by cigarette smoking during one hour as by a strict time schedule. Smoke retention, lung function and blood biomarkers are repeatedly measured.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Groesbeek, Holland
- University Center for Chronic Diseases Dekkerswald
-
Nijmegen, Holland
- Primary care, general practitioners
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- COPD Gold stage II-III (FEV1/FVC<0,70 and FEV1 30-80% of predicted value).
- Current cigarette smoking (at the time of performing the study).
- Willing to provide written informed consent.
- Refrain from smoking and bronchodilators > 8 hours (depends on treatment) before the test.
- Registered in one of the recruitment institutes.
Exclusion Criteria:
- COPD gold stage I or IV.
- Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or reversibility ≥ 10% of predicted.
- Unable to communicate.
- Physically unable to perform any of the tests.
- Non-COPD respiratory disorders.
- Previous lung-volume reduction surgery and/or lung transplantation.
- Evidence of alcohol, drug or solvent abuse.
- Known α-1 antitrypsin deficiency.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: beta 2 agonist + anticholinergic aerosol
|
1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer.
cigarette smoking
Andre navne:
|
|
Placebo komparator: placebo inhalation
|
1 time inhalation of placebo with the amount of puffs similar to the active comparator.
cigarette smoking
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
cigarette smoke retention
Tidsramme: retention measurement is during smoking. smoking is 1 cigarette before and 1 cigarette 45 minutes after medication inhalation for each arm. 1 week between arms
|
retention measurement is during smoking. smoking is 1 cigarette before and 1 cigarette 45 minutes after medication inhalation for each arm. 1 week between arms
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
(hs)CRP
Tidsramme: 3 times within 2 hours for each arm
|
3 times within 2 hours for each arm
|
|
fibrinogen
Tidsramme: 3 times within 2 hours for each arm
|
3 times within 2 hours for each arm
|
|
respiratory function
Tidsramme: at baseline and repeatedly around medication inhalation for 1.5 hours
|
at baseline and repeatedly around medication inhalation for 1.5 hours
|
|
smoking pattern: smoke inhalation and smoke exhalation time and volume
Tidsramme: during smoking cigarettes: twice for each arm.
|
during smoking cigarettes: twice for each arm.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Tjard RJ Schermer, PhD, Radboud University Nijmegen Medical Center
Publikationer og nyttige links
Generelle publikationer
- van Dijk WD, Heijdra Y, Lenders JW, Klerx W, Akkermans R, van der Pouw A, van Weel C, Scheepers PT, Schermer TR. Cigarette smoke retention and bronchodilation in patients with COPD. A controlled randomized trial. Respir Med. 2013 Jan;107(1):112-9. doi: 10.1016/j.rmed.2012.09.019. Epub 2012 Oct 12.
- van Dijk WD, Scheepers PT, Cremers R, Lenders JW, Klerx W, van Weel C, Schermer TR, Heijdra Y. A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial. Trials. 2011 Feb 10;12:37. doi: 10.1186/1745-6215-12-37.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Hjerte-kar-sygdomme
- Lungesygdomme
- Lungesygdomme, obstruktiv
- Lungesygdom, kronisk obstruktiv
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Parasympatholytika
- Autonome agenter
- Agenter fra det perifere nervesystem
- Kolinerge antagonister
- Kolinerge midler
- Adrenerge agonister
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Reproduktive kontrolmidler
- Adrenerge beta-2-receptoragonister
- Adrenerge beta-agonister
- Tokolytiske midler
- Albuterol
- Tiotropiumbromid
Andre undersøgelses-id-numre
- RvB08.066.51196/GE
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .